Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 1,950,000 shares, a drop of 48.7% from the September 30th total of 3,800,000 shares. Based on an average trading volume of 677,200 shares, the short-interest ratio is currently 2.9 days.
Cue Biopharma Trading Down 5.1 %
Shares of Cue Biopharma stock traded down $0.08 during trading on Friday, reaching $1.48. 885,463 shares of the stock were exchanged, compared to its average volume of 437,215. Cue Biopharma has a 1 year low of $0.45 and a 1 year high of $3.25. The firm has a market cap of $71.99 million, a price-to-earnings ratio of -1.40 and a beta of 1.96. The company has a quick ratio of 2.06, a current ratio of 2.06 and a debt-to-equity ratio of 0.11. The stock’s fifty day moving average is $0.87 and its 200 day moving average is $1.16.
Cue Biopharma (NASDAQ:CUE – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. Cue Biopharma had a negative return on equity of 142.93% and a negative net margin of 566.02%. The firm had revenue of $2.66 million for the quarter, compared to analyst estimates of $1.12 million. During the same period last year, the company earned ($0.29) EPS. As a group, equities research analysts expect that Cue Biopharma will post -0.85 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Cue Biopharma
Analyst Ratings Changes
Several research firms have issued reports on CUE. Stifel Nicolaus cut their price target on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. JMP Securities dropped their target price on Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating for the company in a report on Friday, July 26th. Finally, Piper Sandler decreased their price target on Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $5.00.
Read Our Latest Stock Report on CUE
Cue Biopharma Company Profile
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
Featured Articles
- Five stocks we like better than Cue Biopharma
- Best Stocks Under $10.00
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is an Earnings Surprise?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.